Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
08:45am, Wednesday, 17'th Sep 2025
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announce
Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)
01:44pm, Wednesday, 10'th Sep 2025
Akari Therapeutics, Plc (NASDAQ:AKTX ) Discusses at Virtual Investor Closing Bell Series Call Company Participants Abizer Gaslightwala - CEO, President & Director Conference Call Participants Jenene T
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
06:45am, Friday, 05'th Sep 2025
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announce
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
08:30am, Wednesday, 03'rd Sep 2025
Live moderated webcast on Thursday, September 4 th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotech
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
09:15am, Thursday, 14'th Aug 2025
BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
09:15am, Tuesday, 29'th Jul 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 Abizer
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body
Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
08:45am, Tuesday, 22'nd Jul 2025
BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs)
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
09:00am, Wednesday, 25'th Jun 2025
Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-onc
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
09:15am, Thursday, 29'th May 2025
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry l
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
09:00am, Thursday, 22'nd May 2025
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
08:00am, Monday, 19'th May 2025
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rache
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
08:05am, Thursday, 15'th May 2025
Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
08:45am, Thursday, 01'st May 2025
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products
